Application of pharmacogenomics in clinical pharmacology

被引:27
作者
Huang, SM [1 ]
Goodsaid, F [1 ]
Rahman, A [1 ]
Frueh, F [1 ]
Lesko, LJ [1 ]
机构
[1] US FDA, Off Clin Pharmacol & Biopharmaceut, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
基金
美国国家科学基金会;
关键词
pharmacogenomics application; clinical pharmacology;
D O I
10.1080/15376520600558333
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Many factors can affect a patient's response to a drug. These include intrinsic factors such as age, gender, race/ethnicity, genetics, disease states, organ dysfunctions, and other physiological changes, including pregnancy, lactation, and extrinsic factors such as smoking, diet ( food, juice, dietary supplements), and concomitant medications (ICH E5, 1998 and 2004). The interplay of genotypes of the enzymes, transporters and receptors, among other factors ( such as concomitant medications and disease states), can affect the risk/benefit ratio for individual patients. This commentary discusses when the genomic information should be obtained during drug development and when it is to be assimilated into labeling and standards of care that can be used to "individualize" drug therapy and become one of the pillars of "personalized medicine."
引用
收藏
页码:89 / 99
页数:11
相关论文
共 91 条
[1]   Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests [J].
Andersson, T ;
Flockhart, DA ;
Goldstein, DB ;
Huang, SM ;
Kroetz, DL ;
Milos, PM ;
Ratain, MJ ;
Thummel, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :559-581
[2]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[3]  
ANDERSSON T, 2005, FDA PHRMA JHU ED WOR
[4]  
[Anonymous], 2005, FDA DRUG DIAGN COD C
[5]   Identification and functional characterization of new potentially defective alleles of human CYP2C19 [J].
Blaisdell, J ;
Mohrenweiser, H ;
Jackson, J ;
Ferguson, S ;
Coulter, S ;
Chanas, B ;
Xi, T ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2002, 12 (09) :703-711
[6]   Pharmacogenetic study of statin therapy and cholesterol reduction [J].
Chasman, DI ;
Posada, D ;
Subrahmanyan, L ;
Cook, NR ;
Stanton, VP ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (23) :2821-2827
[7]   Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999 [J].
Cross, J ;
Lee, H ;
Westelinck, A ;
Nelson, J ;
Grudzinskas, C ;
Peck, C .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (06) :439-446
[8]  
Dai D, 2001, J PHARMACOL EXP THER, V299, P825
[9]   Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation [J].
Eckhardt, K ;
Li, SX ;
Ammon, S ;
Schänzle, G ;
Mikus, G ;
Eichelbaum, M .
PAIN, 1998, 76 (1-2) :27-33
[10]   Moving towards individualized medicine with pharmacogenomics [J].
Evans, WE ;
Relling, MV .
NATURE, 2004, 429 (6990) :464-468